Clopidogrel-Induced Thrombocytopenia

Incidence and Risk

• Severe cases of thrombotic thrombocytopenic purpura (TTP) were reported in approximately 11 cases among more than 3 million patients treated with clopidogrel, according to the American Heart Association guidelines 1

Management and Monitoring

• Regular monitoring of complete blood counts is recommended, especially during the first few weeks of therapy, as suggested by the American College of Cardiology 1
• Before initiating clopidogrel, consideration of baseline complete blood count is advised, as recommended by the American Heart Association 1
• Clinicians should be vigilant for signs of thrombocytopenia, although routine blood count monitoring is not required for clopidogrel, unlike ticlopidine, as stated by the American College of Cardiology 1

Thrombocytopenia Associated with Antiplatelet Therapy

Incidence and Presentation

• TTP typically occurs within the first 2 weeks of initiating clopidogrel therapy, according to the American College of Chest Physicians 2, 3
• The CAPRIE trial found that the incidence of thrombocytopenia was identical in both clopidogrel and aspirin groups, as reported by the American Heart Association 2, 4

Clinical Features and Management

• The American College of Chest Physicians recommends urgent treatment including plasmapheresis (plasma exchange) for clopidogrel-induced TTP, which can be fatal 2, 3